Deepika Thakur
Senior Director, HEOR
Expertise:
As an accomplished professional in the healthcare industry, Deepika Thakur brings a wealth of experience and expertise to the table. With over a decade of involvement, spanning roles in both industry and healthcare economic consulting firms, Thakur specializes in evidence synthesis and health economic outcomes.
Throughout her career, Deepika has demonstrated proficiency in engaging with internal and external stakeholders, overseeing multifaceted projects, and employing creative problem-solving techniques. Her contributions to complex decision-making and strategic planning have been notable, particularly in their role at Novartis, where they played a pivotal role in developing market access integrated disease and product strategies, thus supporting the successful launch of several products.
She has a history of building, leading, and mentoring teams, as well as serving as a jury member for research presentation awards. Her dedication to driving positive outcomes in health research is underscored by her commitment to excellence and effective communication.
Based in Toronto, Canada, Deepika holds a Master of Pharmacy (Pharmaceutical Chemistry) degree.
Articles by Deepika Thakur
Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability
The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022. The framework guides the planning, conduct and reporting of RWE studies, with the objective of improving the quality and transparency of evidence. The framework has been updated to include guidance on external validity bias and […]
The New AMCP Dossier Format Version 5.0: Key Implications for Strategic Approach
The Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions is the industry standard for communicating clinical and economic information to meet the evidentiary requirements/needs of healthcare decision-makers (HCDMs) in the United States. The latest updates to the AMCP Format (version 5.0, published March 31, 2024) have added guidance on health disparities, real-world evidence […]
Transforming Systematic Literature Reviews: Leveraging AI for Efficiency and Rigor
Systematic literature reviews (SLRs) are instrumental in supporting healthcare decision-making and market access. Traditionally, literature reviews require a resource-intensive process, thus highlighting the need for more efficient methodologies without compromising rigor or integrity. Over the past few years, artificial intelligence (AI) has emerged as a powerful tool that can significantly enhance efficiency in conducting reviews. […]
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from RWD analysis, within the scope of regulatory decision-making. It details the types of studies that can be conducted, how […]